Join us for a comprehensive webinar featuring experts in epigenetics and assay development, focusing on the scientific foundations and applications of Nucleosome Quantification (Nu.Q®) Technology in the realms of drug development and disease monitoring.
Eric A. Ariazi, PhD and Terry Kelly, PhD discuss how nucleosome-based markers are poised to accelerate oncology clinical trials, offering broader applications for monitoring both toxicity and efficacy.
This session explores the critical contributions of Nu.Q® Technology to clinical epigenetics research, emphasizing its role in the identification and validation of biomarkers for epigenetic drug discovery. The technology’s capability in monitoring treatment responses and its utility in elucidating the underlying mechanisms of disease processes are discussed.
Key Topics Include:
- Next-Generation Epigenetic Immunoassay for Quantitative Assessment of Circulating Nucleosomes
- Nu.Q Technology for determining levels of circulating nucleosomes
- Pre-clinical through Clinical Development of Circulating Nucleosomes as Pharmacodynamic Biomarkers in Oncology Trials
- Histone PTMs at biomarkers for therapeutics targeting chromatin regulators
- Liquid biopsy to monitor target engagement of inhibitors of PRC2 subunits including histone methyl transferase EZH2 and its allosteric regulator EED
- Precision oncology strategy for selecting patients with H3K27me3 accumulation
- PD-1/PD-L1 checkpoint inhibitor combination with EZH2i/EEDi
- Expanding Utility of Circulating Nucleosomes to Monitor/Predict Adverse Reactions to CAR-T cell therapy
- Neutrophil release of inflammatory mediators and decondensed DNA (NETosis) before and during the onset of cytokine release syndrome (CRS)
- Monitoring NETosis with Nu.Q
By the end of this discussion, attendees will:
- Gain a nuanced understanding of the emerging opportunities in biomarker-driven, epigenetic therapeutic development.
- Acquire insights into the future potential of nucleosome markers as versatile tools for cancer response and toxicity monitoring.
Presenters
Consultant
Volition
Eric A. Ariazi, PhD, is a distinguished Translational Medicine Scientist with 25+ years of experience spanning academia and industry.
Chief Innovation Officer/Chief Scientific Officer
VolitionRx/Volition America
Dr. Terry Kelly is the Chief Innovation Officer for VolitionRx and Chief Scientific Officer for Volition America.
Production Partner
Additional Content From Scientist.com
Discover the Freshness of Frozen PBMCs – An Assessment of Cryopreservation Impact on T Cell Activation and Phenotype
Discover the impact of cryopreservation of PBMCs on T cell activation and phenotype in Lonza’s free webinar.
Applications of Humanized Mice in the Evaluation of Antibody-Drug Conjugates to Treat Autoimmune Diseases
Join experts from GemPharmatech and BioRay Pharmaceutical as they discuss the use of humanized mice to evaluate antibody-drug conjugates for treating autoimmune diseases.
Related Content
Innovative Approaches to Assessing Thyroid Disruption: The 3D Human Thyroid Microtissue Model
Dr. Chad Deisenroth, PhD, from the US EPA, introduces an advanced human in vitro 3D thyroid microtissue model designed to evaluate thyroid hormone disruption, addressing current challenges with existing models.
Preclinical Animal Models of IBD, GVHD, and Pulmonary Disease
Join BioModels’ Scientists, Andrew Borkowski, PhD and Nicole Smith, PhD, as they discuss a selection of key preclinical models of inflammatory disease, including models of Inflammatory Bowel Disease (IBD)/colitis, Graft vs Host Disease (GvHD), and pulmonary disease, focusing on the utility of clinically relevant endpoints that create highly translational models of human disease.
Applications of Human Intestinal Organoid Cultures in Drug Discovery
Join STEMCELL TEchnologies' experts as they discuss the use of human intestinal organoid cultures in drug discovery and toxicity testing.